Business
Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named
About this update from Editas Medicine, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Judith R. Abrams, M.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Abrams is a leading drug development clinician who has brought multiple medicines from clinical stage development to regulatory approval.\n “We are delighted to have Judith join our leadership at this important juncture for the Company with the recent initiation of the Phase 1/2 Brilliance trial of EDIT-101 (AGN-151587) for the treatment of patients with Leber congenital amaurosis 10 (LCA10),” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine. “Her impressive global clinical experience and her drug development expertise will be instrumental in advancing our mission to develop and deliver transformative medicines to people living with serious diseases.” “Editas Medicine is playing a crucial role in the development of a new class of medicines through CRISPR-based genome editing. It is an exciting time to join the team as we are enrolling the first ever clinical trial to investigate an in vivo CRISPR-based experimental medicine,” said Judith Abrams, M.D., Chief Medical Officer, Editas Medicine. “I am thrilled to join Editas Medicine during this pivotal time and look forward to advancing the EDIT-101 clinical program as well as additional experimental medicines in our pipeline including, EDIT-301 for the treatment of sickle cell disease and future engineered cell medicines for the treatment of cancer.” Dr. Abrams has more than 25 years of experience in leadership roles in the biopharmaceutical industry managing portfolios of products across all phases of global clinical development. Dr. Abrams joins Editas Medicine from EMD Serono Research and Development Institute, Inc., where she served as the Franchise Lead, Immunology and Neurology, Global Drug Safety Innovation. Among her prior roles, Dr. Abrams served as Chief Medical Officer at CorMedix Inc.; Head of Otezla (Apremilast) Global Clinical Submission Team at Celgene Corporation; Vice President, Medical & Science Inflammation at Novo Nordisk, Inc.; Vice President of Clinical Development at NPS Pharmaceuticals, Inc.; Franchise Medical Leader for Reproductive Medicine, Urology, Anti-Infective, Wound Healing and Immu...